CO6640239A2 - Proceso par preparar una composición de inmunoglobulina - Google Patents
Proceso par preparar una composición de inmunoglobulinaInfo
- Publication number
- CO6640239A2 CO6640239A2 CO12211856A CO12211856A CO6640239A2 CO 6640239 A2 CO6640239 A2 CO 6640239A2 CO 12211856 A CO12211856 A CO 12211856A CO 12211856 A CO12211856 A CO 12211856A CO 6640239 A2 CO6640239 A2 CO 6640239A2
- Authority
- CO
- Colombia
- Prior art keywords
- solution
- immunoglobulins
- lgm
- preparation
- immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención hace referencia al campo de las composiciones de inmunoglobulina y su producción a partir de plasma. El objeto de la invención es hacer frente a los inconvenientes de los métodos del estado del arte, tales como la incapacidad para inactivar o eliminar eficazmente los virus sin envoltura y la capacidad limitada para eliminar la actividad proteolítica, manteniendo lgM con alto rendimiento en solución. En consecuencia, la presente invención proporciona un proceso para la preparación de una composición que contiene inmunoglobulina lgM a partir de una fracción de plasma que comprende inmunoglobulinas, comprendiendo dicho proceso:(a) proporcionar una fracción de plasma como una solución que contiene las inmunoglobulinas;(b) mezclar un Ca Cácido carboxílico con la solución y tratar la solución mezcla con un agitador vibratorio para precipitar las proteínas contaminantes; y(c) separar las proteínas precipitadas de la solución para obtener la composición que contiene inmunoglobulina lgM.La invención proporciona, además, la preparación de un anticuerpo que puede obtenerse mediante el proceso anterior y la preparación de un anticuerpo adecuado para ser administrado vía intravenosa en humanos que comprende inmunoglobulinas lgG, IgA e IgM, que tiene una actividad proteolítica de menos de 8 U/I, y en el que al menos el 5% del total de inmunoglobulinas son lgM. Los usos de estas preparaciones de anticuerpos también se proporcionan.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1006753.6A GB201006753D0 (en) | 2010-04-22 | 2010-04-22 | Process for preparing an immunolobulin composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6640239A2 true CO6640239A2 (es) | 2013-03-22 |
Family
ID=42270688
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12211856A CO6640239A2 (es) | 2010-04-22 | 2012-11-22 | Proceso par preparar una composición de inmunoglobulina |
CO12211854A CO6640238A2 (es) | 2010-04-22 | 2012-11-22 | Preparaciones de anticuerpos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12211854A CO6640238A2 (es) | 2010-04-22 | 2012-11-22 | Preparaciones de anticuerpos |
Country Status (20)
Country | Link |
---|---|
US (6) | US8900806B2 (es) |
EP (2) | EP2560682B2 (es) |
JP (4) | JP6283517B2 (es) |
KR (2) | KR101860459B1 (es) |
CN (3) | CN102939107B (es) |
AU (2) | AU2011244241B2 (es) |
BR (2) | BR112012026937A2 (es) |
CA (2) | CA2796409A1 (es) |
CO (2) | CO6640239A2 (es) |
ES (2) | ES2553385T3 (es) |
GB (1) | GB201006753D0 (es) |
HK (2) | HK1177600A1 (es) |
HU (2) | HUE028581T2 (es) |
IL (2) | IL222373A (es) |
MX (2) | MX338195B (es) |
PL (2) | PL2560682T5 (es) |
RU (4) | RU2749732C2 (es) |
SG (2) | SG184843A1 (es) |
WO (2) | WO2011131787A2 (es) |
ZA (2) | ZA201208540B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
FR2959821B1 (fr) * | 2010-05-05 | 2012-07-06 | Lab Francais Du Fractionnement | Procede de mesure de l'activation du complement par des igg |
FR2974301B1 (fr) | 2011-04-20 | 2013-08-23 | Lab Francais Du Fractionnement | Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes |
FR2977893B1 (fr) * | 2011-07-11 | 2015-02-20 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre d'immunoglobulines polyvalentes |
EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
JP2015510875A (ja) | 2012-03-09 | 2015-04-13 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 分泌様免疫グロブリンを含む組成物 |
EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
KR20150115639A (ko) * | 2014-04-04 | 2015-10-14 | 전숙영 | 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제 |
US20170210793A1 (en) * | 2014-07-15 | 2017-07-27 | The Regents Of The University Of California | Novel Treatment for Polycystic Kidney Disease |
PL3334747T3 (pl) | 2015-08-13 | 2024-04-02 | Amgen Inc. | Naładowana filtracja wgłębna białek wiążących antygen |
ES2881201T3 (es) * | 2016-03-14 | 2021-11-29 | Biotest Ag | Tratamiento de la neumonía grave adquirida en la comunidad |
EP3275897A1 (en) | 2016-07-27 | 2018-01-31 | Biotest AG | Process for preparing immunoglobulin compositions |
RU2660584C1 (ru) * | 2017-06-06 | 2018-07-06 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ определения FC-функции препаратов иммуноглобулина человека |
WO2019105916A1 (en) * | 2017-11-29 | 2019-06-06 | F. Hoffmann-La Roche Ag | Target interference suppressed anti-drug antibody assay |
EP3747903A1 (en) | 2019-06-07 | 2020-12-09 | Biotest AG | Method and kit for testing potency of immunoglobulin compositions |
EP4132573A1 (en) * | 2020-04-10 | 2023-02-15 | Vanudis GmbH | Natural antibodies in prophylaxis and therapy |
TW202200205A (zh) * | 2020-06-03 | 2022-01-01 | 愛爾蘭商格里佛全球營運有限公司 | 超免疫igg及/或igm組合物及其製備方法及從供體中獲得超免疫人血漿的方法 |
CA3183021A1 (en) * | 2020-07-10 | 2022-01-13 | Myles Lindsay | Method for obtaining a composition comprising human plasma-derived immunoglobulin m |
CN111944043B (zh) * | 2020-09-01 | 2023-05-09 | 华兰生物工程重庆有限公司 | 一种从血浆废弃物中提取IgM的方法 |
WO2022106546A1 (en) | 2020-11-19 | 2022-05-27 | Biotest Ag | Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19 |
AU2022317368A1 (en) | 2021-07-29 | 2024-02-22 | Csl Behring Ag | Method of purifying immunoglobulin g and uses thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US136556A (en) | 1873-03-04 | Improvements in button-fastenings | ||
DE2901822A1 (de) * | 1979-01-18 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt |
US4371520A (en) * | 1981-10-28 | 1983-02-01 | The Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
DE3310150A1 (de) * | 1983-03-21 | 1984-09-27 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation |
IL90281A (en) † | 1988-06-06 | 1994-10-07 | Miles Inc | Preparations containing MGI antibodies |
DE3825429C2 (de) * | 1988-07-27 | 1994-02-10 | Biotest Pharma Gmbh | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt |
US4939176A (en) | 1988-12-20 | 1990-07-03 | Miles Inc. | Viral inactivation process |
DE3927111C3 (de) * | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate |
DE3927112C1 (es) † | 1989-08-17 | 1990-10-25 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
US5367054A (en) * | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
EP0840624B1 (fr) | 1995-07-14 | 2007-07-25 | CAF - DCF cvba - scrl | Installation d'inactivation de contaminants viraux presents dans des produits sanguins |
EP0764658B1 (de) | 1995-09-22 | 2002-01-02 | ZLB Bioplasma AG | Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen |
EP0835880A1 (de) | 1996-10-14 | 1998-04-15 | Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk | Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation |
JP3987599B2 (ja) * | 1996-12-05 | 2007-10-10 | 日本製薬株式会社 | 筋ジストロフィー治療剤 |
JPH10167894A (ja) * | 1996-12-11 | 1998-06-23 | Mitsubishi Gas Chem Co Inc | ビスマス置換希土類鉄ガーネット単結晶膜の製造法 |
US6955917B2 (en) * | 1997-06-20 | 2005-10-18 | Bayer Healthcare Llc | Chromatographic method for high yield purification and viral inactivation of antibodies |
US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
AU753468B2 (en) | 1998-06-09 | 2002-10-17 | Csl Behring Ag | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
RU2178309C2 (ru) * | 2000-01-12 | 2002-01-20 | Российский научно-исследовательский институт геронтологии | Антитимоцитарный глобулин для внутривенного введения и способ его получения |
RU2192279C2 (ru) * | 2000-09-07 | 2002-11-10 | Нижегородское государственное предприятие по производству бактерийных препаратов | Способ получения иммуноглобулинового препарата |
CA2428332C (en) † | 2000-11-13 | 2010-05-25 | Bayer Aktiengesellschaft | Method of inactivating microorganisms in a fluid using ultraviolet radiation |
FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
US7727974B2 (en) | 2001-08-10 | 2010-06-01 | Eisai R & D Management Co., Ltd. | Methods of reducing the severity of mucositis |
WO2003037504A1 (fr) † | 2001-11-02 | 2003-05-08 | Japan Techno Co., Ltd. | Agitateur vibratoire pour sterilisation et sterilisateur ainsi que procede de sterilisation faisant appel a cet agitateur vibratoire |
RU2255766C2 (ru) * | 2003-03-05 | 2005-07-10 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" | Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата |
WO2004087735A2 (en) | 2003-03-26 | 2004-10-14 | The University Of Texas | Proteolytic and covalent antibodies |
ES2418830T3 (es) | 2003-10-27 | 2013-08-16 | Wyeth Llc | Retirada de agregados de alto peso molecular usando cromatografía de hidroxiapatita |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
MXPA06008435A (es) | 2004-01-30 | 2007-05-23 | Suomen Punainen Risti Veripalvelu | Proceso de manufactura de una inmunoglobulina libre de virus. |
DK1718675T3 (da) | 2004-02-27 | 2013-07-15 | Octapharma Ag | Fremgangsmåde til at tilvejebringe en oprenset virussikker antistoftilberedning |
DK1830881T3 (da) | 2004-12-10 | 2010-09-20 | Novimmune Sa | Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf |
WO2006064373A2 (en) | 2004-12-16 | 2006-06-22 | Genzyme Polyclonals S.A.S. | Methods of purifying immunologlobulins |
KR101157174B1 (ko) | 2005-11-24 | 2012-06-20 | 삼성전자주식회사 | 세포 또는 바이러스의 신속한 파괴 방법 및 장치 |
DE102005062634A1 (de) | 2005-12-23 | 2007-06-28 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung |
FR2899111B1 (fr) * | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. |
FR2899112B1 (fr) * | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament. |
US8354076B2 (en) † | 2006-10-02 | 2013-01-15 | Palo Alto Research Center Incorporated | Fluid stirring mechanism |
EP1950225A1 (de) | 2007-01-25 | 2008-07-30 | Octapharma AG | Verfahren zur Steigerung von Proteinausbeuten |
AU2009246510B2 (en) † | 2008-05-12 | 2014-02-13 | Strox Biopharmaceuticals, Llc | Staphylococcus aureus-specific antibody preparations |
RU2457861C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов |
RU2457863C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов |
GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
NZ591514A (en) | 2011-03-03 | 2013-11-29 | Kode Biotech Ltd | Assay method |
-
2010
- 2010-04-22 GB GBGB1006753.6A patent/GB201006753D0/en not_active Ceased
-
2011
- 2011-04-21 RU RU2017111820A patent/RU2749732C2/ru active
- 2011-04-21 AU AU2011244241A patent/AU2011244241B2/en active Active
- 2011-04-21 SG SG2012076055A patent/SG184843A1/en unknown
- 2011-04-21 MX MX2012012263A patent/MX338195B/es active IP Right Grant
- 2011-04-21 HU HUE11715928A patent/HUE028581T2/en unknown
- 2011-04-21 KR KR1020127030528A patent/KR101860459B1/ko active IP Right Grant
- 2011-04-21 RU RU2012149743A patent/RU2612899C2/ru active
- 2011-04-21 RU RU2012149741A patent/RU2617532C2/ru active
- 2011-04-21 CA CA2796409A patent/CA2796409A1/en not_active Abandoned
- 2011-04-21 EP EP11715567.1A patent/EP2560682B2/en active Active
- 2011-04-21 JP JP2013511592A patent/JP6283517B2/ja active Active
- 2011-04-21 EP EP11715928.5A patent/EP2560691B1/en active Active
- 2011-04-21 MX MX2012012262A patent/MX337060B/es active IP Right Grant
- 2011-04-21 BR BR112012026937A patent/BR112012026937A2/pt not_active Application Discontinuation
- 2011-04-21 HU HUE11715567A patent/HUE025853T2/en unknown
- 2011-04-21 WO PCT/EP2011/056487 patent/WO2011131787A2/en active Application Filing
- 2011-04-21 KR KR1020127030527A patent/KR101872747B1/ko active IP Right Grant
- 2011-04-21 ES ES11715928.5T patent/ES2553385T3/es active Active
- 2011-04-21 PL PL11715567.1T patent/PL2560682T5/pl unknown
- 2011-04-21 CN CN201180029337.XA patent/CN102939107B/zh active Active
- 2011-04-21 PL PL11715928T patent/PL2560691T3/pl unknown
- 2011-04-21 CN CN201611045494.0A patent/CN107080842A/zh active Pending
- 2011-04-21 CN CN201180029338.4A patent/CN102939111B/zh active Active
- 2011-04-21 AU AU2011244240A patent/AU2011244240B2/en active Active
- 2011-04-21 CA CA2796263A patent/CA2796263C/en active Active
- 2011-04-21 JP JP2013511591A patent/JP6118248B2/ja active Active
- 2011-04-21 RU RU2016140455A patent/RU2765738C2/ru active
- 2011-04-21 SG SG2012076063A patent/SG184844A1/en unknown
- 2011-04-21 WO PCT/EP2011/056486 patent/WO2011131786A2/en active Application Filing
- 2011-04-21 BR BR112012026934A patent/BR112012026934A2/pt not_active Application Discontinuation
- 2011-04-21 ES ES11715567.1T patent/ES2551605T3/es active Active
-
2012
- 2012-10-11 IL IL222373A patent/IL222373A/en active IP Right Grant
- 2012-10-11 IL IL222374A patent/IL222374A/en active IP Right Grant
- 2012-10-19 US US13/655,686 patent/US8900806B2/en active Active
- 2012-10-19 US US13/655,649 patent/US9243056B2/en active Active
- 2012-11-13 ZA ZA2012/08540A patent/ZA201208540B/en unknown
- 2012-11-13 ZA ZA2012/08541A patent/ZA201208541B/en unknown
- 2012-11-22 CO CO12211856A patent/CO6640239A2/es unknown
- 2012-11-22 CO CO12211854A patent/CO6640238A2/es not_active Application Discontinuation
-
2013
- 2013-05-07 HK HK13105491.8A patent/HK1177600A1/zh unknown
- 2013-07-08 HK HK13107957.1A patent/HK1180601A1/zh unknown
-
2014
- 2014-10-31 US US14/529,400 patent/US9518110B2/en active Active
-
2016
- 2016-06-01 JP JP2016110121A patent/JP6612182B2/ja active Active
- 2016-06-15 JP JP2016118887A patent/JP6612186B2/ja active Active
- 2016-11-10 US US15/348,121 patent/US10059759B2/en active Active
-
2018
- 2018-07-09 US US16/029,781 patent/US10954290B2/en active Active
-
2021
- 2021-02-05 US US17/168,848 patent/US11780909B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6640239A2 (es) | Proceso par preparar una composición de inmunoglobulina | |
Ren et al. | Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates | |
MX2020003888A (es) | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. | |
Ellebedy et al. | Re-engaging cross-reactive memory B cells: the influenza puzzle | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
Fontana et al. | Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate | |
AR076800A1 (es) | Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento | |
HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
BR112015022790A8 (pt) | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral | |
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
ECSP11010823A (es) | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos | |
BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
RU2009148886A (ru) | Рсв-специфичные связывающие молекулы и средства для их получения | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
AU2009353693A1 (en) | RSV-specific binding molecule | |
IN2014DN10288A (es) | ||
AR118850A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
RU2014147741A (ru) | Модифицированные области антител и их применение | |
RU2014140744A (ru) | Композиции, содержащие секреторноподобные иммуноглобулины | |
RU2014100107A (ru) | Лечение нарушений свертываемости крови путем введения рекомбинантного фв | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
Loomis et al. | Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine | |
BR112022003740A2 (pt) | Anticorpos anti-cd96 e métodos de uso dos mesmos |